Immunotherapy in Ovarian Cancer: Are We There Yet?-Reference-Cited by-同舟云学术

Immunotherapy in Ovarian Cancer: Are We There Yet?

Published:2019-09-20 Issue:27 Volume:37 Page:2460-2471
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Kandalaft Lana E.¹,Odunsi Kunle²,Coukos George¹

Affiliation:

1. Ludwig Institute for Cancer Research and University of Lausanne, Lausanne, Switzerland

2. Roswell Park Comprehensive Cancer Center, Buffalo, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.19.00508

Reference179 articles.

1. International Agency for Research on Cancer: Estimated number of incident cases from 2018 to 2040, ovary, females, all ages, in Organization WH (ed), 2019

2. Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer

3. The blockade of immune checkpoints in cancer immunotherapy

4. Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy

5. Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The unveiled mosaic of intra-tumor heterogeneity in ovarian cancer through spatial transcriptomic technologies: A systematic review;Translational Research;2024-11

2. Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study;British Journal of Cancer;2024-09-11

3. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

4. Immunostimulatory CKb11 gene combined with immune checkpoint PD-1/PD-L1 blockade activates immune response and simultaneously overcomes the immunosuppression of cancer;Bioactive Materials;2024-09

5. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial;Med;2024-08